## Cyrus Poonawalla Group

"SAROSH BHAVAN", 16-B/1, DR. AMBEDKAR ROAD, PUNE - 411 001, INDIA. ■TEL.: +91-20-26137221-5 ■ FAX: +91-20-26133228 CIN U80903PN1984PTC032945

Date: 12-10-2022

The Manager, Listing Departments, The National Stock Exchange of India Ltd. Exchange Plaza, C-1, Block G. Bandra Kurla Complex, Bandra (E), Mumbai-400051 NSE Symbol: PANACEABIO Bombay Stock Exchange Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001 BSE Scrip Code: 531349

## Subject: <u>Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011</u>

Dear Sir/Madam,

We would like to inform you, as required under the provisions of Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulation, 2011 in respect of our dealings in the shares of Target Company – Panacea Biotec Limited listed over your Stock Exchange.

Please find enclosed the said declaration made in our capacity as 'Acquirer' and also on behalf of others, in their capacity as 'Person Acting in Concert', as required under the aforesaid Regulation.

Kindly acknowledge the receipt of the same.

Yours faithfully,

For Serum Institute of India Private Limited

**Authorised Signatory** 

## Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	PANACEA BIOTEC LTD		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Acquirer:  1. Serum Institute of India Private Limited PAC's:  2. Chakan Investment Private Limited (Holding Nil shares) 3. Corpint Investments Private Limited(Holding Nil shares) 4. Fortune Intercontinental Private Limited(Holding Nil shares) 5. Cyza Chem Private Limited(Holding Nil shares) 6. Naukhal Investment Private Limited (Holding Nil shares)		
Whether the acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	NSE, BSE		
Details of the acquisition / disposal as follows	Number		
Before the acquisition under consideration, holding of:  a) Shares carrying voting rights b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	60,18,022 9.83% 9.83%		
<ul> <li>c) Voting rights (VR) otherwise than by shares</li> <li>d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each</li> </ul>			
category) e) Total (a+b+c+d)	60,18,022 9.83% 9.83%		
Details of acquisition/sale			
a) Shares carrying voting rights acquired/sold			
Shares carrying voting rights acquired/sold	13,45,981 2.20% 2.20%		
<ul> <li>b) VRs acquired /sold otherwise than by shares</li> <li>c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold</li> </ul>			

d) Shares encumbered / invoked/released by the acquirer e) Total (a+b+c+/-d)	13,45,981	2.20%	2.20%	
5) Total (4 5 5 7 4)	15,15,761	2.2070	2.2070	
After the acquisition/sale, holding of:				
a) Shares carrying voting rights	46,72,041	7.63%	7.63%	
b) Shares encumbered with the acquirer	-	-	-	
c) VRs otherwise than by shares				
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying	-	-	-	
voting rights in the TC (specify holding in each category) after acquisition	-	-	-	
e) Total (a+b+c+d)	46,72,041	7.63%	7.63%	
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Open Market			
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	11 <sup>th</sup> October, 2022			
Equity share capital / total voting capital of the TC before the said acquisition / sale	6,12,50,746			
Equity share capital/ total voting capital of the TC after the said acquisition / sale	6,12,50,746	6,12,50,746		
Total diluted share/voting capital of the TC after the said acquisition	6,12,50,746			

(\*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

For Serum Institute of India Private Limited

Authorised Signatory

Place: Pune

Date: 12th October, 2022